Literature DB >> 15371877

Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.

Henrik Suttmann1, Marc Jacobsen, Karina Reiss, Dieter Jocham, Andreas Böhle, Sven Brandau.   

Abstract

PURPOSE: Natural killer (NK) cells are of crucial importance for bacillus Calmette-Guerin (BCG) mediated antitumor effects. We defined the mechanisms of BCG mediated NK cell activation in vitro.
MATERIALS AND METHODS: A standard Cr release assay was used to measure the cytotoxicity of BCG activated NK cells. Using the MACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany) we depleted various immune cell subpopulations from BCG stimulated peripheral blood mononuclear cells to phenotype activated NK cells. During the stimulation process anticytokine antibodies and recombinant cytokines were added to define their role in NK cell activation. For costimulation studies peripheral blood mononuclear cells were separated into lymphocytes and monocytes by counterflow-centrifugation (elutriation). Inhibitory NK cell receptor expression on activated NK cells was measured by flow cytometry by antiCD3, antiCD56 and anti-inhibitory NK cell receptor triple staining.
RESULTS: The accessory function of monocytes was indispensable for BCG mediated NK cell activation. However, the stimulatory potential of monocytes did not require direct cell-cell contact to NK cells or major histocompatibility complex dependent antigen presentation to T cells. Monocyte derived interleukin (IL)-12 and to a lesser extent interferon (IFN)-alpha were key mediators for stimulating BCG induced NK cell cytotoxicity and IFN-gamma production. In contrast, IL-10 inhibited NK cell cytotoxicity and IL-18 did not show any effect. Exogenous recombinant IFN-alpha and IL-12 enhanced BCG mediated secretion of IFN-gamma and yet BCG induced NK cell cytotoxicity remained unchanged. While the CD158a and CD158b subsets did not have a significant role, NKG2A cells represented the predominant cytolytic subset in BCG activated NK cells.
CONCLUSIONS: Following BCG stimulation the monocyte derived TH1 cytokines IL-12 and IFN-alpha activate tumor cytotoxic CD3/CD56/NKG2A NK cells. Our results elucidate NK activating mechanisms that are operative during BCG immunotherapy for bladder cancer and are relevant for an early, innate antimycobacterial immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371877     DOI: 10.1097/01.ju.0000131944.52354.63

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.

Authors:  Eva M García-Cuesta; Gloria Esteso; Omodele Ashiru; Sheila López-Cobo; Mario Álvarez-Maestro; Ana Linares; Mei M Ho; Luis Martínez-Piñeiro; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

3.  FimH can directly activate human and murine natural killer cells via TLR4.

Authors:  M Firoz Mian; Nicole M Lauzon; David W Andrews; Brian D Lichty; Ali A Ashkar
Journal:  Mol Ther       Date:  2010-05-04       Impact factor: 11.454

4.  BCG stimulated dendritic cells induce an interleukin-10 producing T-cell population with no T helper 1 or T helper 2 bias in vitro.

Authors:  Jeppe Madura Larsen; Christine Stabell Benn; Yvonne Fillie; Desiree van der Kleij; Peter Aaby; Maria Yazdanbakhsh
Journal:  Immunology       Date:  2007-03-20       Impact factor: 7.397

5.  Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?

Authors:  Mar Valés-Gómez
Journal:  Transl Androl Urol       Date:  2019-12

6.  Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.

Authors:  Guo-qing Ding; Yan-lan Yu; Zhou-jun Shen; Xie-lai Zhou; Shan-wen Chen; Guo-dong Liao; Yue Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-05       Impact factor: 3.066

7.  The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Authors:  Alexandre R Zlotta; Neil E Fleshner; Michael A Jewett
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

9.  Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Authors:  Feng Lang; Ma Linlin; Tian Ye; Zhang Yuhai
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

Review 10.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.